Plasma Expander Market - Global Industry Size, Share, Trends, Opportunity, and Forecast, 2021-2031

The Global Plasma Expander Market is projected to escalate from USD 8.25 Billion in 2025 to USD 16.91 Billion by 2031, reflecting a compound annual growth rate of 12.71%. These specialized intravenous solutions, consisting of crystalloids and colloids, are essential for restoring circulating blood volume and maintaining oncotic pressure in patients experiencing trauma, hypovolemic shock, or burns. The market is primarily driven by the urgent need for fluid resuscitation in emergency medicine and the growing volume of major surgical interventions globally that demand precise hemodynamic stabilization. This trend is supported by recent procedural data; according to the International Society of Aesthetic Plastic Surgery, in 2025, reports indicated that over 17.4 million surgical procedures were conducted worldwide in the previous year, highlighting a continuous need for effective perioperative volume replacement therapies.

However, market growth faces significant obstacles due to safety concerns regarding the adverse physiological effects of specific synthetic colloids. Regulatory authorities have issued warnings and restrictive guidelines linking hydroxyethyl starches to risks such as coagulopathy and renal impairment. These clinical risks have prompted healthcare providers to adopt a cautious approach, often substituting synthetic options with human albumin or crystalloids. This regulatory scrutiny, combined with the rigorous pharmacovigilance required for these products, acts as a major barrier to the broader adoption and expansion of the synthetic plasma expander segment.

Market Drivers

The increasing incidence of road accidents and traumatic injuries serves as a primary catalyst for the Global Plasma Expander Market's growth. Severe physical trauma and high-impact collisions require immediate fluid resuscitation to manage hypovolemic shock and effectively restore intravascular volume. In these emergency situations, plasma expanders are crucial for maintaining tissue perfusion and hemodynamic stability until the patient stabilizes or blood products become available. This urgent clinical necessity is underscored by recent accident data; according to the National Highway Traffic Safety Administration, April 2024, in the 'Early Estimate of Motor Vehicle Traffic Fatalities in 2023', approximately 40,990 individuals died in motor vehicle traffic crashes in the United States, emphasizing the persistent demand for trauma-related volume replacement therapies.

Simultaneously, the rising prevalence of chronic cardiovascular disorders is significantly boosting the demand for specialized volume replacement therapies. Patients with compromised cardiac function often undergo complex surgeries or require meticulous fluid management, utilizing synthetic expanders or human albumin to maintain oncotic pressure without overloading the circulatory system. The burden of these conditions is growing, necessitating frequent medical interventions and perioperative support. According to the American Heart Association, January 2024, in the 'Heart Disease and Stroke Statistics 2024 Update', nearly 48.6 percent of U.S. adults have some form of cardiovascular disease. This prevalence drives the consumption of plasma derivatives in surgical wards, contributing to the financial growth of major industry players; for instance, according to CSL Limited, in 2024, the company reported total revenue of 14.8 billion USD, reflecting strong performance in their albumin and critical care portfolios.

Market Challenges

A primary obstacle hindering the growth of the Global Plasma Expander Market is the significant safety concern regarding the adverse physiological effects of synthetic colloids, particularly hydroxyethyl starches. Regulatory bodies have identified serious clinical risks associated with these products, including coagulopathy and renal impairment. Consequently, strict guidelines and black box warnings have been issued, compelling healthcare providers to exercise caution when prescribing these solutions. This regulatory pressure impedes market growth by driving a shift in clinical preference towards crystalloids or human albumin, thereby reducing the commercial adoption of higher-margin synthetic expanders in critical care settings.

The impact of these safety restrictions is especially detrimental given the large volume of patients in segments where these products are now contraindicated, such as burn management. According to the American Burn Association, in 2024, the organization reported that annual national hospital burn admissions reached 29,165. Although this patient population represents a critical demographic requiring extensive fluid resuscitation, the prohibition of synthetic colloids for burn injuries due to kidney toxicity risks effectively eliminates this demand from the addressable market. This exclusion of a key patient segment directly limits the revenue potential and expansion of the synthetic plasma expander sector.

Market Trends

Innovation in portable and shelf-stable formulations for military combat care is transforming the market by addressing the logistical challenges of traditional frozen plasma. Standard plasma requires strict cold-chain maintenance, making deployment difficult in battlefield environments where immediate fluid resuscitation is vital. Manufacturers are therefore accelerating the development of spray-dried and freeze-dried products that allow for rapid reconstitution at the point of injury, effectively bypassing the need for refrigeration. This technological progress is highlighted by recent clinical milestones; according to Velico Medical, August 2025, in the 'FrontlineODP Spray Dried Plasma Achieves Key Milestone' announcement, the company successfully completed its first-in-human Phase I clinical trial for a spray-dried plasma system, demonstrating safety for deployment in austere military settings.

Furthermore, the strategic vertical integration of plasma collection networks to secure supply has become a decisive trend as fractionators prioritize raw material self-sufficiency. Companies are optimizing donor center operations and implementing technologies to enhance yield, ensuring a consistent stream of plasma for high-demand derivatives. This focus on supply chain control mitigates shortages and directly supports commercial expansion by stabilizing production costs. According to Grifols, February 2025, in the 'Full Year 2024 Results' report, the company's Biopharma division achieved a revenue growth of 11.3 percent at constant currency, a performance attributed to the successful execution of plasma supply improvements and cost-per-liter reductions across its global network.

Key Players Profiled in the Plasma Expander Market

• Baxter International Inc.
• Fresenius SE & Co. KGaA
• CSL Limited
• Grifols, S.A.
• B. Braun Melsungen AG
• Hikma Pharmaceuticals PLC
• Octapharma AG
• Kedrion S.p.A.
• Shanghai RAAS Blood Products Co., Ltd.
• Terumo Corporation

Report Scope

In this report, the Global Plasma Expander Market has been segmented into the following categories:

Plasma Expander Market, by Product Type:

• Dextran
• Hydroxyethyl Starch
• Human Albumin
• PEGylated Albumin
• Polyvinylpyrrolidone (PVP)
• Gelatin

Plasma Expander Market, by End User:

• Online Pharmacies
• Retail Pharmacies
• Hospital Pharmacies

Plasma Expander Market, by Region:

• North America
• Europe
• Asia-Pacific
• South America
• Middle East & Africa

Competitive Landscape

Company Profiles: Detailed analysis of the major companies present in the Global Plasma Expander Market.

Available Customization

The analyst offers customization according to your specific needs. The following customization options are available for the report:

• Detailed analysis and profiling of additional market players (up to five).

This product will be delivered within 1-3 business days.